NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Subsidiary Partners with iNGENu CRO to Initiate MS Clinical Study
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, through its subsidiary, HUGE Biopharma Australia Pty Ltd., entered into agreement with iNGENu CRO Pty Ltd. The agreement outlines plans to conduct a phase 1 study. The randomized, double-blind, placebo-controlled, multiple ascending dose study is designed to evaluate the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants. A patented new chemical entity, Lucid-21-302 is a first-in-class, nonimmunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis…







